Kornimate/medical-research-clean huggingface dataset:
left cardiac chambers size in obese individuals and its relation to bmi and waist circumference

Conditions: Obesity

Summary: aim of study: to determine if there is relation between left cardiac chambers size ,bmi and waist circumference in obese individuals. 1. primary outcomes: -to determine if there is relation between left cardiac chambers size ,bmi and waist circumference in obese individuals. 2. secondary outcomes: * to determine the effect of obesity on heart health in obese individuals.

body mass index and waist circumference are important measurements of our bodies as they can affect our health.the person is obese if he has bmi equal 30 or higher.increased risk of obesity related disease occurs in men with waist circumference equal 102 cm or more and woman with waist circumference equals 88 cm or more. increasing bmi and waist circumference can increase risk of type 2 diabetes mellitus ,hypertension ,cardiovascular disease and cerebrovascular accidents.there are many diseases that can affect left cardiac chambers size like aortic, mitral valvediseases,hypertension and atherosclerosis.screening of patients heart by echocardiography allow us to detect changes in the muscle of heart and this allow doctors to put treatment plan to patient to prevent heart health from deterioration. in this study the investigators want to know if there an association between left cardiac chambers size ,bmi and waist circumference in obese individuals.

Eligibility criteria:
inclusion criteria: * 1-patient age 18 years old or above. 2-patient bmi 30kg/m2 or higher . 3-patient waist circumference in men 102cm or more and in women 88cm or more. 4-obese patient with comorbidities (e.g dm,htn). exclusion criteria: * 1-patient age 18 years old. 2-patient bmi less than 30 kg/m2. 3-patient waist circumference in men less than 102cm and in women less than 88cm.
vidéolaryngoscopy study of the lpec in obese patients

Conditions: Videolaryngoscopy

Summary: 1. check the intubation conditions during laryngoscopy without external mobilization of the larynx, with sellick manoeuvre or with low paratracheal esophagal compression in obese patient 2. international surveys comparing tracheal intubation difficulty on a scale of 1 to 3 between cricoid pressure, left paratracheal esophageal compression and neutral position

check the intubation conditions during laryngoscopy without external mobilization of the larynx, with sellick manoeuvre or with low paratracheal esophagal compression in obese patient international surveys comparing tracheal intubation difficulty on a scale of 1 to 3 between cricoid pressure, left paratracheal esophageal compression and neutral position

Eligibility criteria:
inclusion criteria: * adults patients with bmi \> 35 undergoing general anaesthesia exclusion criteria: * pregnant women * people with facial * oropharyngeal abnormalities
minimizing post-surgical pain and narcotic administration through cryotherapy

Conditions: Urologic Surgical Procedure

Summary: postoperative pain is an unavoidable consequence of open abdominal surgery. although cryotherapy, the application of ice to a surgical wound site, has been shown to be effective in reducing postoperative pain in orthopedic, gynecologic, and hernia operations, it has not been assessed in patients who undergo major open abdominal operations. we hypothesized that patients who receive cryotherapy would report lower pain scores as a primary outcome measure. this would result in less narcotic analgesia usage, and shorter hospital stays as secondary outcome measures.

objectives: this study will attempt to assess the impact of cryotherapy on post-surgical inflammation and narcotic use. end-points for the study will be patient use of narcotics and pain level, regularly measured by nursing staff. patient selection: this study will accept all consecutive consenting patients who visit the grady hospital and emory university urology clinics who require abdominal surgery.the study will require 55 patients, based on prior power calculations. registration/randomization: because this study will enroll all consenting patients, no registration is required. patients will be enrolled by their urologist during a standard visit. with consent, the urologist will direct the patient to the researcher. patients will be randomized to either cryotherapy or no adjunctive therapy following abdominal surgery. therapy: patients in the cryotherapy study group will have ice packs placed on their abdominal wound for 24 hours following surgery.after 24 hours, patients had the option of using ice packs for as long as they wished. patient assessment: patients will be assessed by the nursing staff as they would otherwise be assessed postsurgically. data collection: during recovery time in the hospital, nurses will monitor both groups of patients as they do all patients. as with all patients, nurses will ask about pain levels and check the amount of narcotics you require for pain control. this study will not require any additional effort on patients' part. once they are discharged, patient participation in the study will be complete.

Eligibility criteria:
inclusion criteria: * any open transperitoneal abdominal surgery with a midline incision exclusion criteria: * additional surgeries required

Keywords: abdominal surgery cryotherapy pain score narcotic utilization
explore the mechanisms of pruritus in bullous pemphigoid patients during remission

Conditions: Bullous Pemphigoid; Pruritus

Summary: the following is the investigators hypothesis regarding the pruritus of bp patients during remission. anti-bp 180 ige binds to dermal mast cells, inducing their activation and secretion of mediators after being cross-linked by antigens. among mediators, histamine directly induces itching and vessel changes, whereas tryptase potentiates itching and vessel changes in an indirect way through the actions of neuropeptides. tryptase stimulates neurons which in turn secrete neuropeptides.

bullous pemphigoid(bp) is a cutaneous autoimmune blister disease. in addition to blisters formation which disrupt skin barrier and result in high mortality, erythematous edematous plaques often develop on skin of bullous pemphigoid patients accompanied with intensive pruritus. as regard with the pathogenesis of bp, it is generally accepted that anti-bp180 igg is the most important pathogenic factor for blister formation, whereas anti-bp180 ige which binds to mast cells and induces their activation results in erythematous edematous plaques. quite a few bullous pemphigoid patients suffer from intensive pruritus even during clinical remission period that means blisters or plaques are no longer on their skin. the reasons why pruritus persists during this period are still obscure. pruritus is the most common symptom of cutaneous diseases. our understanding regarding pathophysiology of "pruritus" has made a remarkable progress in the past decade. now, it is known that there are various kinds of substances that induce pruritus (pruritus mediators) and different combinations of these mediators are involved in different itching diseases. moreover, neuropeptides secreted by stimulated neurons can in turn induce neurogenic inflammation. the following is our hypothesis regarding the pruritus of bp patients during remission. anti-bp 180 ige binds to dermal mast cells, inducing their activation and secretion of mediators after being cross-linked by antigens. among mediators, histamine directly induces itching and vessel changes, whereas tryptase potentiates itching and vessel changes in an indirect way through the actions of neuropeptides. tryptase stimulates neurons which in turn secrete neuropeptides. thus, in order to test our hypothesis, the strategy of this study is to compare parameters between two groups of patients, bullous pemphigoid patients in remission with pruritus and without pruritus. the following parameters in serum and skin will be measured: total ige, anti-bp 180 ige, the number and activated status of mast cells, the amount of some mediators and neuropeptides produced by mast cells and neurons, respectively. in addition, these parameters in active stage will also be measured for reference and with a hope to find useful parameters for predicting the persistence of pruritus in remission.

Eligibility criteria:
inclusion criteria: * patients with bullous pemphigoid exclusion criteria: * patients have other disorders which can lead to itching sensation
arresting vertical transmission of hepatitis b virus

Conditions: Hepatitis B; Vertical Transmission of Infectious Disease

Summary: the purpose of this pilot study is to demonstrate the feasibility of adding hbv screening and treatment of pregnant women to the existing hiv pmtct platform in order to prevent mother-to-child transmission of hepatitis b virus.

hepatitis b virus (hbv) is a leading cause of chronic liver disease globally, with devastating complications such as cirrhosis, hepatocellular carcinoma and death. vertical transmission (vt) of hbv is a worldwide public health concern because infected children are at high risk of developing chronic liver disease. it is a particular problem in the democratic republic of the congo (drc); preliminary data suggest that approximately 3% of children have hbv infection due to vt. however, vt is preventable. pregnant women with risk factors can be identified and treatments given which can virtually eliminate transmission. unfortunately, despite the high burden of hbv, neither hbv testing of pregnant women nor interventions to prevent hbv vt are routinely performed in the drc and elsewhere in sub-saharan africa. this pilot feasibility study will address this healthcare gap by identifying women with hbv early in their pregnancies and intervening to prevent vt by (1) treating mothers with high-risk hbv (defined as hbeag positivity and/or hbv viremia \>10\^6) with tenofovir and (2) providing hbv vaccine to hbv-exposed infants within 24 hours of birth. this pilot study will piggyback onto an existing study that is evaluating the drc's hiv prevention of maternal-to-child transmission option b+ (pmtct+) strategy. combining programs to prevent vt of hbv and hiv enables using the same personnel and infrastructure to implement both interventions. furthermore, tenofovir, used to treat hbv infections, is already used in the drc to treat hiv. researchers hypothesize that utilizing the existing pmtct+ infrastructure in the drc will provide a cost-effective platform to prevent hbv vt. if effective, this model of treatment will inform future public health efforts and wider policy recommendations that can be applied in the drc and throughout the sub-saharan african region to reduce the burden of hbv.

Eligibility criteria:
inclusion criteria: * pregnant women receiving care at binza and kingasani maternity centers presenting prior to 24 weeks gestation * infants born to hbv-positive women exclusion criteria: * participants who are severely sick and who require prolonged hospitalization. * any women who do not intend to stay in kinshasa for prenatal care through delivery
effects of whole body vibration therapy on cognitive function, balance, and quality of life in older adults with mild cognitive impairment

Conditions: Cognitive Impairment; Balance; Quality of Life

Summary: this is a double-blind, randomized controlled trial comparing wbv therapy with a placebo intervention and standard care. a total of 150 participants will be recruited and investigated from prince mutib hospital. participants will be randomly allocated to one of three groups: wbv therapy, placebo (non-vibrating platform), or control (standard care). the study duration will be 12 weeks, with assessments conducted at baseline, post-intervention (12 weeks), and at a 6-month follow-up. protocol parameters summary * session frequency: 3 times per week. * session duration: 25 minutes per session. * vibration frequency: 30 hz. * amplitude: 1-2 mm. * program duration: 12 weeks.


Eligibility criteria:
inclusion criteria: * adults aged 60 years and older. * diagnosed with mild cognitive impairment (montreal cognitive assessment (moca) score of 18-25). one point is added if years of education are less than 12 years\[2\]. * able to stand independently or with minimal assistance. * no contraindications for wbv therapy or exercise. exclusion criteria: * diagnosis of dementia. * severe musculoskeletal or neurological disorders. * implanted electronic medical devices (e.g., pacemaker). * inability to comprehend study instructions.
the combination of adductor canal block and periarticular injection. a novel technique for patients undergoing total knee replacement (acb pai)

Conditions: Osteoarthritis

Summary: total knee replacement is associated with severe post-operative pain. the purpose of this study is to compare two methods of treatment for pain control following total knee replacement with an accelerated physical therapy protocol to aid the achievement of rehab milestones.

a total of 106 patients undergoing total knee arthroplasty will be randomized into two groups: one to receive only periarticular injections and the other periarticular injections and adductor canal block. patients will be asked their numeric pain scores before surgery as baseline and at 24 and 48 hours post-operation. patients also will be asked questions from painout questionnaire at 24 and 48 hours. time to reach discharge criteria based on physical therapy assessments will also be measured.

Eligibility criteria:
inclusion criteria: * patients with osteoarthritis scheduled for primary tricompartmental total knee arthroplasty with a participating surgeon * age 18 to 80 years * planned use of regional anesthesia * ability to follow study protocol * english speaking (secondary outcomes include questionnaires validated in english only) exclusion criteria: hepatic or renal insufficiency patients younger than 18 years old and older than 80 patients intending to receive general anesthesia patients planning to go to rehab post operatively patients scheduled to go into the or after 1 pm allergy or intolerance to one of the study medications patients with an asa of iv chronic gabapentin/pregabalin use (regular use for longer than 3 months) chronic opioid use (taking opioids for longer than 3 months) diabetes patients on workers compensation or disability

Keywords: nerve block rehabilitation knee replacement, total
transcranial direct current stimulation in autistic spectrum disorder

Conditions: Autistic Disorders Spectrum

Summary: to understand the changes in the resting electroencephalogram (eeg) brain networks of children and adolescents with autistic spectrum disorder (asd) induced by transcranial direct current stimulation (tdcs), we asked two questions. first: how can tdcs modulate the expression of neural network dynamics? second: how can tdcs modulate functional connections at specific frequencies? we hypothesized that the tdcs mechanism results in increased cortical frequencies in the areas under the anode, which may reflect an increase in synaptic connectivity, and that this tdcs-related increase changes connection profiles at specific frequencies important for asd, indicating improvement in symptoms. to verify this improvement, the researchers used the autism treatment evaluation checklist (atec) after an intervention, comparing baseline scores with post-treatment scores.


Eligibility criteria:
inclusion criteria: patients with asd reported by a neuropediatrician; age group between 5 and 18 years; mild and moderate clinical symptoms exclusion criteria: patients with severe mental illness; use of a pacemaker or other metal device on the body; brain tumor or intracranial infection; uncooperative parents or caregivers; epilepsy; structural change in the skull

Keywords: autism tdcs eeg
a phase 2 trial to evaluate the efficacy and safety of ocv-501 in elderly patients with acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: to compare disease-free survival in patients 60 years or older with acute myeloid leukemia (aml) who are randomly assigned to receive either ocv-501 monotherapy or placebo.


Eligibility criteria:
inclusion criteria: * patients with aml who achieved first complete remission within one or two courses of standard induction therapy, and completed standard consolidation therapy (more than one course). * patients who are 60 years or older. * patients who have provided written informed consent within 90 days from the last dose of consolidation therapy on an informed consent form that has been approved by an institutional review board or independent ethics committee. exclusion criteria: * patients who have acute promyelocytic leukemia (apl) with t(15;17) (q22;q12), (pml/rara) karyotype abnormalities, and other variant types. * patients who are scheduled for hematopoietic stem cell transplantation. * patients who have received drugs potentially affecting the immune system within 4 weeks before starting imp administration or who may receive such drugs after start of the trial. * patients who have a severe concurrent disease or psychiatric illness likely to interfere with participation in this trial. * patients who are hiv antibody positive, hbv-dna positive or have unrecovered chronic hepatitis c with positive hcv antibody. * patients who have cirrhosis. * patients judged to be ineligible by the investigator (or subinvestigator) for any other reasons.

Keywords: ocv-501 acute myeloid leukemia antigen specific cancer immunotherapeutic
ontario icu clinical best practices demonstration project

Conditions: Ventilator Acquired Pneumonia; Catheter Related Blood Stream Infections; Pressure Ulcer Prophylaxis; DVT Prophylaxis; Restrictive Blood Transfusion Strategy; Daily Spontaeous Breathing Trials

Summary: the pragmatic issue at hand how to get physicians and nurses to use best practices... and how to measure consequences of their implementation. this is the science of "knowledge translation", which we are realizing is an "organic" entity. as part of our critical care strategy our goal is to improve the quality and continuity of critical care within our health care system. toward this goal we are implementing a program which links 16 ontario hospitals through their critical care units in a provincial network.


Eligibility criteria:
inclusion criteria: * cohort of hospitals with intensive care units in ontario

Keywords: best practices, performance improvement, intensive care, measurement
pazopanib in advanced and cisplatin-resistant germ cell tumors

Conditions: Germ Cell Tumors; Measurable Disease

Summary: this is an open label, single arm, single center, phase 2 study with the use of the antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell tumors who are not cured following first or subsequent chemotherapy lines for metastatic disease, followed by eventual surgery.


Eligibility criteria:
inclusion criteria: * male gender. * confirmation of gct histology based on pathologic review at fondazione int milan. * unequivocal progression of measurable disease. * a minimum of 2 and a maximum of 3 platinum-based chemotherapy lines for metastatic disease. * first-line therapy should consist of at least 3 cycles of cisplatin-based chemotherapy. * prior single, tandem or triple high-dose chemotherapy course given as front-line or salvage therapy is allowed. exclusion criteria: * failure to meet any of the above inclusion criteria. * concurrent treatment with other cytotoxic drugs or targeted therapies. * prior radiation therapy within 14 days of trial start.

Keywords: testicular cancer germ cell tumors salvage therapy pazopanib
68ga-nota-aca-bbn(7-14) pet/ct in patients with primary gliomas

Conditions: Glioma

Summary: this is an open-label positron emission tomography/computed tomography (pet/ct) study to investigate the diagnostic performance and evaluation efficacy of 68ga-nota-aca-bbn(7-14) in glioma patients. a single dose of 111-148 mega-becquerel (mbq) 68ga-nota-aca-bbn(7-14) will be injected intravenously. visual and semiquantitative method will be used to assess the pet/ct images.

non-invasive imaging evaluation of grpr expression would be of great help in drug development, patient stratification and therapeutic response monitoring. various grpr targeting imaging probes have been develop to meet the purpose. bombesin (bbn) is an amphibian homolog of mammalian gastrin-releasing peptide (grp). bbn(7-14), with the amino acid sequence of gln-trp-ala-val-gly-his-leu-met-nh2, has been extensively used for the development of molecular probes for the imaging of gastrin-releasing peptide receptor (grpr), after being labeled with various radionuclides. multiple preclinical studies have demonstrated receptor-specific accumulation of the tracers in grpr positive tumors. for interests in clinical translation of 68ga-nota-aca-bbn(7-14), an open-label dynamic whole-body pet/ ct study was designed to investigate the safety and diagnostic performance of 68ga-nota-aca-bbn(7-14) in patients with glioma.

Eligibility criteria:
inclusion criteria: * must be able to provide a written informed consent * clinically based and magnetic resonance imaging (mri)-based suspected newly diagnosed primary glioma. * the tumor will be surgically removed and histological diagnosis will be available. exclusion criteria: * females planning to bear a child recently or with childbearing potential； * known severe allergy or hypersensitivity to iv radiographic contrast； * inability to lie still for the entire imaging time because of cough, pain, etc. * inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc. * concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance.

Keywords: pet/ct bombesin gastrin-releasing peptide receptor 68gallium labeling
predictive factors and autonomy level change

Conditions: Memory Impairment

Summary: the alzheimer's disease or related disorders (adrd) are among the most disabling diseases because of their main features such as cognitive impairment, loss of functional autonomy and behavioural disorders. in absence of current curative treatment, the identification of the predictive risk factors of progression of the disease, evaluated through its main symptoms, represents a major stake of public health. the investigators aimed at developing a database, which includes the patient medical records on a prospective basis, in collaboration with the medical and administrative personal and with the university hospital computer science department. the main objective is to study the predictive factors associated with the change of functional autonomy level, measured every 6 months to 12 months by phone, in a memory clinic. the study population would consist in about 1000 patients with adrd. the length of follow-up of each patient will be 3 years.


Eligibility criteria:
inclusion criteria: * patients who undergo a medical visit in the memory clinic for the 1st time * patients living at home or in housing * patients with memory impairment, at all stage of the disease exclusion criteria: * patients in institution * patients under legal protection * patients with a hearing or visual impairment, which dot not allow to carry out the examination

Keywords: alzheimer's disease or related disorders functional autonomy level cognitive function predictive factors